In a new study it was demonstrated that a compound derived from Rosmarinic Acid (RosA) have powerful anti-arthritic effects through combination of immunosuppressive and anti-inflammatory actions, in a Collagen-Induced Arthritis (CIA) model1.
Rosmarinic acid is a natural compound found in rosemary, sweet basil and perilla. RosA is known to have a wide range of immune-modulating activity by regulating oxidative stress2. In recent years some studies have reported that RosA has an anti-inflammatory activity can be used to treat various inflammatory disorders3.
Rheumatoid Arthritis (RA) is an unceasing provocative disease that has specific symptom such as synovitis and joint damage. Many genetic and environmental factors are responsible for this disease. Complications like; synovial cell proliferation, lymphocyte infiltration and cartilage and bone destruction are biggest concern. Many studies have been done in different animal models to find proper drugs4.
Many drugs are used as immunosuppressive agents and some of them have harmful effects for liver and kidney5,6. Thus, it is still needed to develop the novel immunosuppressive drug that have low side-effect but high selectivity for the clinical application.
Scientists found the anti-rheumatoid arthritis activity of methyl ester form (RosA-Me) by adapting collagen-induced arthritis mouse model, a kind of the conventional of in vivo tests for T-cell mediated diseases1.
As the study authors said:
“In this report, among these models, by using Collagen-Induced Arthritis (CIA) mouse model, we describe the development of the potent anti-rheumatoid arthritis compound derived from rosmarinic acid and the evaluation of the activity. As explained before, we demonstrated that RosA, an lck SH2 inhibitor, suppresses T-cell function via dual mechanism such as inhibition of T-cell activation and lck-dependent apoptosis induction. RosA-Me inhibits the activity of lck-SH2 domain and the expression of IL-2 gene inducing immune response, leading to the inhibition of immune response in vivo and in vitro. Therefore, RosA-Me can be effectively used for inhibiting lck SH2 domain which can be applied to suppressing graft rejection, autoimmune diseases and inflammatory diseases.”
Many studies were done to find potential derivatives of RosA In conclusion, RosA-Me has sufficient high activity even at low dosages than the parent RosA for CIA mouse model, so RosA-Me can be used as novel treatment agents for arthritis diseases.
Your email address will not be published. Required fields are marked *
17 November, 2019